Bicara therapeutics reports third quarter 2024 financial results and provides business update

On track to initiate fortifi-hn01, a pivotal phase 2/3 trial of ficerafusp alfa in 1l r/m hnscc completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 boston, nov. 12, 2024 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended september 30, 2024 and provided a business update. “the third quarter of 2024 was momentous for bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional egfr/tgf-Β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said claire mazumdar, phd, mba, chief executive officer of bicara therapeutics.
BCAX Ratings Summary
BCAX Quant Ranking